- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||otelixizumab|
|Search PubMed titles||otelixizumab|
|Search PubMed titles/abstracts||otelixizumab|
|Otelixizumab is a chimeric humanized IgG1 monoclonal antibody targeting the CD3E component of the T cell receptor. The antibody is aglycosylated. Otelixizumab was investigated as a potential treatment for autoimmune diseases including type I diabetes [3-4].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.